Reshma L. Mahtani, DO

home / authors / reshma-l-mahtani-do

Articles

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Stephanie L. Graff, MD, FACP;Reshma L. Mahtani, DO;Kelly E. McCann, MD, PhD;Hope S. Rugo, MD

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Dr Mahtani on Addressing Unmet Needs in Breast Cancer

Reshma L. Mahtani, DO

April 1st 2024

Reshma L. Mahtani, DO, discusses how attempts to address unmet needs in breast cancer have evolved over time.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

Reshma L. Mahtani, DO

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Dr Mahtani on Unique Challenges Women in Oncology Experience During Career Transitions

Reshma L. Mahtani, DO

March 19th 2024

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Dr Mahtani on Treatment Sequencing in HER2+ Metastatic Breast Cancer

Reshma L. Mahtani, DO

April 12th 2023

Reshma Lillaney Mahtani, DO, discusses available therapies in the first-, second-, and later-line settings in patients with HER2-positive metastatic breast cancer.

Dr. Mahtani on Side Effects of Ovarian Suppression in Breast Cancer

Reshma L. Mahtani, DO

April 9th 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses side effects of ovarian suppression in patients with breast cancer.

Dr. Mahtani on TEXT and SOFT Trial Data in HR+ Breast Cancer

Reshma L. Mahtani, DO

April 5th 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the updated data from the TEXT and SOFT clinical trials in premenopausal women with hormone-receptor positive (HR+) breast cancer.

Dr. Mahtani on the Use of CDK 4/6 Inhibitors in Metastatic ER+ Breast Cancer

Reshma L. Mahtani, DO

March 23rd 2018

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.